Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN – Get Free Report) was the recipient of some unusual options trading on Wednesday. Wall Street Zen downgraded Eledon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 16th. Get Eledon Pharmaceuticals alerts:View Our Latest Stock Analysis on Eledon PharmaceuticalsInstitutional Inflows and OutflowsEledon Pharmaceuticals Stock PerformanceSeveral hedge funds and other institutional investors have recently modified their holdings of ELDN. Eledon Pharmaceuticals Company Profile(Get Free Report)Eledon Pharmaceuticals, Inc (NASDAQ:ELDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of therapies for diseases characterized by smooth muscle dysfunction. Further ReadingReceive News & Ratings for Eledon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eledon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.